# Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

> **NCT02027454** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 42 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** GSK1265744
- **DRUG:** GSK1265744 matching placebo
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT02027454
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2014-06-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02027454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02027454, "Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT02027454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*